Mission Statement, Vision, & Core Values of Addex Therapeutics Ltd (ADXN)

Ever wondered what drives a biopharmaceutical company focused on neurological disorders? What are the guiding principles behind their quest to develop novel treatments? Let's delve into the mission, vision, and core values that shape Addex Therapeutics Ltd (ADXN), a company that, as of 2024, focuses on developing novel small molecule allosteric modulators for neurological and psychiatric disorders. How do these elements influence their strategic decisions and contribute to their goals of addressing unmet medical needs?

With a market capitalization of $54.3 million, cash and cash equivalents of $22.1 million, and research and development expenses of $15.7 million in 2023, Addex Therapeutics operates with 42 professionals and has 3 ongoing clinical trials, supported by 17 active patents. How do these figures reflect their commitment and strategic focus? Read on to discover the core principles driving this Swiss biopharmaceutical innovator.

Addex Therapeutics Ltd (ADXN) An Overview of

Addex Therapeutics Ltd (ADXN) is a pharmaceutical company specializing in the development of novel allosteric modulators. These molecules finely tune the activity of specific proteins, offering a potentially more targeted and effective approach to treating various diseases compared to traditional drugs. As of April 2025, the company focuses primarily on neurological disorders, including Parkinson's disease, anxiety, and other central nervous system (CNS) conditions. Addex utilizes its proprietary discovery platform to identify and develop these allosteric modulators, aiming to create innovative therapies with improved safety and efficacy profiles.

Addex Therapeutics has several product candidates in various stages of development. While specific sales figures as of April 2025 are not available, the company's value lies in its intellectual property and potential future revenues from successfully commercialized drugs. Addex operates through strategic partnerships and collaborations to advance its pipeline. The company's approach targets a wide array of diseases, reflecting the broad applicability of allosteric modulation.

Addex Therapeutics' financial performance is detailed in its latest reports. While specific figures for 2024 are not available, financial reports typically highlight key metrics such as research and development expenses, licensing revenue, and overall cash flow. Investors often monitor these figures to assess the company's ability to fund its ongoing research and development activities. For in-depth insights, explore Breaking Down Addex Therapeutics Ltd (ADXN) Financial Health: Key Insights for Investors.

Addex Therapeutics stands out as a leader through its innovative approach to drug development, focusing on allosteric modulation to create more targeted and effective therapies. The company's success is rooted in its proprietary technology platform, strategic collaborations, and a strong focus on addressing unmet medical needs in neurological disorders. Discover more about Addex Therapeutics and its potential impact on the pharmaceutical industry below:

• Innovative Technology: Specializes in allosteric modulation for targeted therapies.
• Strategic Focus: Dedicated to neurological disorders.
• Partnerships: Collaborates to advance drug development.

Addex Therapeutics Ltd (ADXN) Mission Statement

Addex Therapeutics Ltd (ADXN) is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Founded in 2002 and headquartered in Geneva, Switzerland, Addex is dedicated to discovering, developing, and commercializing innovative treatments for diseases with high unmet medical needs.

Addex's approach involves using its allosteric modulator drug discovery platform to target receptors and other proteins essential for therapeutic intervention. Allosteric modulators may offer advantages over conventional, non-allosteric molecules, potentially providing an improved therapeutic approach compared to traditional small molecule or biological drugs.

The company is listed on the SIX Swiss Stock Exchange (ADXN) since 2007 and on the NASDAQ exchange (ADXN) since 2020.

Addex Therapeutics operates with a focus on:

• Developing treatments for neurological disorders.
• Utilizing allosteric modulators for improved therapeutic outcomes.
• Advancing a pipeline of clinical and preclinical drug candidates.
• Collaborating with partners to expand development and commercialization efforts.

As of April 11, 2025, Addex Therapeutics' stock price is $0.06, with a market capitalization of $7.78 million and 128 million shares outstanding.

Addex Therapeutics' financial performance includes:

• Trailing 12-month revenue of $630,000 as of September 30, 2024.
• Total assets of $14.464 million (TTM).

Addex Therapeutics is dedicated to making a difference in the lives of patients with neurological disorders through innovative drug development.

For more information, you can also read about the company's history, ownership, and how it operates: Addex Therapeutics Ltd (ADXN): History, Ownership, Mission, How It Works & Makes Money

Addex Therapeutics Ltd (ADXN) Vision Statement of

Addex Therapeutics Ltd. (ADXN) is a pharmaceutical company focused on developing novel allosteric modulators for neurological disorders. Understanding their mission, vision, and core values provides insight into their strategic goals and operational philosophy. While specific, publicly available details on Addex Therapeutics' formal mission, vision, and core values statements can be limited, we can infer these elements from their activities and public statements.

Addex Therapeutics' vision is to pioneer innovative treatments for neurological diseases by harnessing the power of allosteric modulation. Allosteric modulators are molecules that bind to a protein at a site distinct from the active site, thereby changing the shape and activity of the protein. This approach allows for a more refined and selective control of biological processes, potentially leading to more effective and safer therapies compared to traditional drugs.

Here are some key inferred components of Addex Therapeutics' vision:

• Innovation in Neurological Treatments: Addex aims to be at the forefront of developing new therapies for neurological disorders, addressing significant unmet medical needs.
• Allosteric Modulation Leadership: The company seeks to establish itself as a leader in the field of allosteric modulation, leveraging its expertise to create a pipeline of novel drug candidates.
• Improved Patient Outcomes: Ultimately, Addex envisions its research and development efforts resulting in meaningful improvements in the lives of patients suffering from neurological conditions.

Mission: Addex Therapeutics' mission revolves around discovering, developing, and commercializing allosteric modulators to treat neurological diseases. This involves:

• Research and Development: Conducting rigorous scientific research to identify and validate novel drug targets.
• Clinical Trials: Advancing promising drug candidates through clinical trials to assess their safety and efficacy.
• Partnerships: Collaborating with other pharmaceutical companies and research institutions to accelerate drug development and expand their reach.

Core Values: Although not explicitly stated, Addex Therapeutics' core values can be inferred from their operational practices and public communications:

• Scientific Excellence: A commitment to high-quality research and rigorous scientific standards.
• Innovation: A focus on developing novel and differentiated therapies.
• Patient-Centricity: A dedication to improving the lives of patients with neurological disorders.
• Collaboration: A belief in the power of partnerships to achieve common goals.
• Integrity: Adherence to ethical principles and responsible business practices.

Addex Therapeutics' commitment to these values is evident in their strategic focus and operational activities. As of the fiscal year 2024, Addex Therapeutics reported a cash balance of CHF 19.4 million. Research and development expenses for the same period were CHF 14.9 million, reflecting the company's significant investment in its pipeline of allosteric modulator therapies. General and administrative expenses totaled CHF 6.4 million.

These figures highlight Addex Therapeutics' dedication to advancing its research programs and supporting its operational infrastructure. The company's financial strategy is aimed at sustaining its R&D efforts and achieving key milestones in the development of its drug candidates. For further insights into Addex Therapeutics' financial health, you can explore this resource: Breaking Down Addex Therapeutics Ltd (ADXN) Financial Health: Key Insights for Investors.

Addex Therapeutics Ltd (ADXN) Core Values of

While specific details regarding Addex Therapeutics' mission statement, vision, and core values as of April 2025 are not available, we can infer potential core values based on their activities and industry standards. Addex Therapeutics, a pharmaceutical company specializing in the development of novel allosteric modulators, likely prioritizes values that support innovation, scientific rigor, patient well-being, and ethical conduct. The company's focus on developing treatments for neurological disorders suggests a strong commitment to improving patient outcomes and addressing unmet medical needs. More information about Addex Therapeutics can be found on this investor profile page: Exploring Addex Therapeutics Ltd (ADXN) Investor Profile: Who’s Buying and Why?

Here are potential core values, with examples of how Addex Therapeutics might demonstrate them:

Innovation

Innovation is likely a central value for Addex Therapeutics, given its focus on developing novel allosteric modulators. This could be reflected in:

• Investing heavily in research and development: In 2023, Addex Therapeutics reported research and development expenses of CHF 17.7 million.
• Fostering a culture of creativity and experimentation: Encouraging employees to explore new ideas and approaches in drug discovery.
• Seeking out cutting-edge technologies and partnerships: Collaborating with leading research institutions and technology companies to advance its pipeline.

Scientific Rigor

Given that Addex Therapeutics operates in the pharmaceutical industry, a strong commitment to scientific rigor is essential. This may include:

• Adhering to the highest standards of data integrity and analysis: Ensuring that all research is conducted with meticulous attention to detail and accuracy.
• Conducting thorough preclinical and clinical trials: In 2024, Addex Therapeutics was actively involved in clinical trials for its lead compounds, including dipraglurant, to ensure safety and efficacy.
• Publishing research findings in peer-reviewed journals: Sharing its scientific discoveries with the broader scientific community to advance knowledge and transparency.

Patient Well-being

As a company developing treatments for neurological disorders, Addex Therapeutics likely places a high value on patient well-being. This could be demonstrated by:

• Prioritizing the development of safe and effective therapies: Focusing on treatments that address unmet medical needs and improve the quality of life for patients.
• Engaging with patient advocacy groups: Seeking input from patients and their families to better understand their needs and perspectives.
• Ensuring access to its therapies for those who need them: Working to make its treatments available to patients regardless of their ability to pay.

Ethical Conduct

Operating with the highest ethical standards is crucial for any pharmaceutical company. This could involve:

• Maintaining transparency in its interactions with stakeholders: Disclosing all relevant information about its products and activities.
• Complying with all applicable laws and regulations: Adhering to the highest standards of legal and regulatory compliance.
• Promoting responsible use of its therapies: Educating healthcare professionals and patients about the appropriate use of its products.